Literature DB >> 10366114

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline.

E Yelin1, L A Wanke.   

Abstract

OBJECTIVE: To describe the distribution of direct medical care costs of rheumatoid arthritis (RA) over 1-year and 11-year periods, and to evaluate the impact of poor function and functional decline on direct costs.
METHODS: The present study uses data from the University of California, San Francisco, RA Panel Study in which 1,156 persons with RA have been followed up for as long as 15 years through annual structured interviews and periodic updates on severity from rheumatologists. We present annual direct medical care cost data for the years 1995 and 1996 and estimates of cumulative costs for the period 1986-1996 for the 272 persons followed up continuously for this period.
RESULTS: Medical care costs for RA averaged $5,919 a year from a societal perspective; persons with RA incur another $2,582 in medical care costs for non-RA reasons. Of the RA total costs, hospital admissions account for more than half. Costs are highly skewed, with the costs in the 90th, 95th, and 100th percentiles totaling $8,209, $31,059, and $85,469 a year, respectively. Cumulative costs for the period 1986-1996 averaged $57,201, with cumulative costs in the 90th, 95th, and 100th percentiles totaling $114,844, $142,563, and $191,540, respectively. Persons with RA in the worst quartile of function experienced total annual direct costs that were 2.55 times as high and total hospital costs that were 6.97 times as high as those in the best (e.g., the first) quartile. Poor baseline functional status and declining functional status had similar, large effects on cumulative medical care costs.
CONCLUSION: Medical care costs for RA over 1 year and 1 decade are highly skewed. Persons with RA with poor and declining function experience much higher costs of care.

Entities:  

Mesh:

Year:  1999        PMID: 10366114     DOI: 10.1002/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  64 in total

Review 1.  Appropriate and effective management of rheumatoid arthritis.

Authors:  F C Breedveld; J R Kalden
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

2.  Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients.

Authors:  Kaleb Michaud; Gene Wallenstein; Frederick Wolfe
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-11-15       Impact factor: 4.794

Review 3.  Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Authors:  Eleanor M Heather; Katherine Payne; Mark Harrison; Deborah P M Symmons
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

4.  Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Authors:  Ashit Syngle; Sudeep Kaur; Inderjeet Verma; Tanya Syngle; Vijaita Syngle
Journal:  Clin Rheumatol       Date:  2017-06-21       Impact factor: 2.980

Review 5.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.

Authors:  Peter K Schädlich; Henning Zeidler; Angela Zink; Erika Gromnica-Ihle; Matthias Schneider; Christoph Straub; Josef G Brecht; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Healthcare costs associated with elderly chronic pain patients in primary care.

Authors:  Aida Lazkani; Tiba Delespierre; Bernard Bauduceau; Florence Pasquier; Philippe Bertin; Gilles Berrut; Emmanuelle Corruble; Jean Doucet; Bruno Falissard; Francoise Forette; Olivier Hanon; Linda Benattar-Zibi; Celine Piedvache; Laurent Becquemont
Journal:  Eur J Clin Pharmacol       Date:  2015-05-26       Impact factor: 2.953

Review 8.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011.

Authors:  Sharan K Rai; J Antonio Aviña-Zubieta; Natalie McCormick; Mary A De Vera; Diane Lacaille; Eric C Sayre; Hyon K Choi
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-05       Impact factor: 4.794

10.  Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

Authors:  Michael H Schiff; Elaine B Yu; Michael E Weinblatt; Larry W Moreland; Mark C Genovese; Barbara White; Amitabh Singh; Yun Chon; J Michael Woolley
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.